Palmar Hyperhidrosis – Pipeline Insight, 2020

DelveInsight’s, “Palmar Hyperhidrosis – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Palmar Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Palmar Hyperhidrosis Understanding
Palmar Hyperhidrosis: Overview
Palmar hyperhidrosis, or excessive hand sweating, is a common condition affecting 1-3% of the population. It usually starts in childhood or adolescence. Sweaty hands can significantly affect a person socially and emotionally.
Many factors can contribute to the condition, including genetic influences as well as physical and emotional stress. A family history is present in up to 30% of cases. Palmar hyperhidrosis affects both hands equally and can range from mild clammy hands to severe sweating. It stops when sleep.
Diagnosis
The diagnosis is usually made based on a history of excessive sweating. No investigations are needed.
Treatment
Treatment will depend on how severe the sweating is and which previous treatments have been successful. Topical treatments
• Topical treatments: Some mild to moderate cases can respond to topical treatments such as aluminium chloride hexahydrate (Driclor).
• Iontophoresis may be considered for cases which do not respond to topical treatments.
• Botox injections can treat sweaty hands safely and effectively. However, the treatment is not subsidised under Medicare-PBS and the cost limits its wider use.
• Anticholinergic tablets (such as oxybutynin and propantheline bromide) can be useful in treating palmar hyperhidrosis. However, side effects such as constipation, dry mouth and drowsiness are common.
• Endoscopic thoracic sympathectomy (ETS) is a surgical treatment option for various forms of hyperhidrosis
Palmar Hyperhidrosis Emerging Drugs Chapters
This segment of the Palmar Hyperhidrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Palmar Hyperhidrosis Emerging Drugs
• Glycopyrronium: Dermira
Glycopyrronium is a Muscarinic receptor antagonists that is being developed by Dermira for the treatment of Palmar Hyperhidrosis. It is currently in phase II stage of development.
• TC-5214: Atacama Therapeutics
TC-5214 (dexmecamylamine) is a single isomer of mecamylamine that inhibits α3β4 nicotinic receptors and is a potent nicotine acetylcholine antagonist. Low doses of TC-5214 will inhibit primary hyperhidrosis in all localizations. Currently, Atacama is testing TC-5214 in a Phase 2 clinical trial for palmar hyperhidrosis.
Further product details are provided in the report……..
Palmar Hyperhidrosis: Therapeutic Assessment
This segment of the report provides insights about the different Palmar Hyperhidrosis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Palmar Hyperhidrosis
There are approx. 5+ key companies which are developing the therapies for Palmar Hyperhidrosis. The companies which have their Palmar Hyperhidrosis drug candidates in the most advanced stage, i.e. phase III include Atacama Therapeutics and others
• Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Palmar Hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type
Products have been categorized under various Molecule types such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Palmar Hyperhidrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Palmar Hyperhidrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmar Hyperhidrosis drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Palmar Hyperhidrosis R&D. The therapies under development are focused on novel approaches to treat/improve Palmar Hyperhidrosis.
• In February 2020, Eli Lilly and Company announced the successful completion of its acquisition of Dermira, Inc.
Palmar Hyperhidrosis Report Insights
• Palmar Hyperhidrosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Palmar Hyperhidrosis Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Palmar Hyperhidrosis drugs?
• How many Palmar Hyperhidrosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Palmar Hyperhidrosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Palmar Hyperhidrosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Palmar Hyperhidrosis and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Dermira
• Atacama Therapeutics
• Stiefel, a GSK Company
• Brickell Biotech
• Allergan

Key Products
• Glycopyrronium
• Dexmecamylamine
• Umeclidinium
• BBI-4000
• BTX-A